Dasatinib and docetaxel in advanced prostate cancer

The Lancet Oncology

Volumn 14, Issue 13, 2013, Pages 1248-1249

  Lara, Primo N ^a   Evans, Christopher P ^b  

^a Division of Hematology Oncology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DASATINIB; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL SURVIVAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; HUMAN; INTRACELLULAR SIGNALING; LETTER; METASTASIS POTENTIAL; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SAMPLE SIZE; STUDY DESIGN; TARGET CELL; TREATMENT OUTCOME; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84888129102     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70500-X     Document Type: Letter

References (10)

1. Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2013, published online Nov 8. http://dx.doi.org/10.1016/S1470-2045(13)70479-0.
2. Antonarakis ES, Eisenberger MA Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 2013, 31:1709-1712.
3. Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012, 118:63-71.
4. Twardowski PW, Beumer JH, Chen CS, et al. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs 2013, 24:743-753.
5. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009, 101:263-268.
6. Mendiratta P, Mostaghel E, Guinney J, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009, 27:2022-2029.
7. Fizazi K The role of Src in prostate cancer. Ann Oncol 2007, 18:1765-1773.
8. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 27:6365-6375.
9. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009, 69:151-160.
10. Wu Z, Chang PC, Yang JC, et al. Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. Genes Cancer 2010, 1:40-49.